Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine Bell

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
BMC Urology|November 8, 2020
Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)Andrea Necchi, Hiroyuki Nishiyama, Nobuaki Matsubara, et al.
Pediatric Research|January 9, 2024
Lactoferrin intake from maternal milk during the neonatal hospitalization and early brain development among preterm infantsAgata M P Atayde, Neena R Kapoor, Sara Cherkerzian, et al.
Investigational New Drugs|November 11, 2019
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancerJohanna C Bendell, Helge G Bischoff, Jimmy Hwang, et al.
International Forum of Allergy & Rhinology|August 25, 2022
Genetics of denatonium-responsive bitter receptors in aspirin-exacerbated respiratory diseaseJennifer E Douglas, Cailu Lin, Corrine J Mansfield, et al.
Journal of Environmental Management|January 28, 2026
How operational strategies influence nitrogen removal and nitrous oxide emissions: Insights from a full-scale wastewater treatment plantMostafa Khalil, Marwan Alsaleh, Ahmed Elsayed, et al.
Gynecologic Oncology|March 31, 2015
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group studyRobert L Coleman, Michael W Sill, Katherine Bell-McGuinn, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2024
Worldwide study of the taste of bitter medicines and their modifiersHa Nguyen, Cailu Lin, Katherine Bell, et al.
Chemical Senses|February 4, 2025
Worldwide study of the taste of bitter medicines and their modifiersHa Nguyen, Cailu Lin, Katherine Bell, et al.
Molecular Cancer Therapeutics|April 19, 2017
Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor ErdafitinibJayaprakash D Karkera, Gabriela Martinez Cardona, Katherine Bell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 StudyBenoit You, Vasudha Sehgal, Balakrishna Hosmane, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
BMC Urology|November 8, 2020
Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)Andrea Necchi, Hiroyuki Nishiyama, Nobuaki Matsubara, et al.
Pediatric Research|January 9, 2024
Lactoferrin intake from maternal milk during the neonatal hospitalization and early brain development among preterm infantsAgata M P Atayde, Neena R Kapoor, Sara Cherkerzian, et al.
Investigational New Drugs|November 11, 2019
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancerJohanna C Bendell, Helge G Bischoff, Jimmy Hwang, et al.
International Forum of Allergy & Rhinology|August 25, 2022
Genetics of denatonium-responsive bitter receptors in aspirin-exacerbated respiratory diseaseJennifer E Douglas, Cailu Lin, Corrine J Mansfield, et al.
Journal of Environmental Management|January 28, 2026
How operational strategies influence nitrogen removal and nitrous oxide emissions: Insights from a full-scale wastewater treatment plantMostafa Khalil, Marwan Alsaleh, Ahmed Elsayed, et al.
Gynecologic Oncology|March 31, 2015
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group studyRobert L Coleman, Michael W Sill, Katherine Bell-McGuinn, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2024
Worldwide study of the taste of bitter medicines and their modifiersHa Nguyen, Cailu Lin, Katherine Bell, et al.
Chemical Senses|February 4, 2025
Worldwide study of the taste of bitter medicines and their modifiersHa Nguyen, Cailu Lin, Katherine Bell, et al.
Molecular Cancer Therapeutics|April 19, 2017
Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor ErdafitinibJayaprakash D Karkera, Gabriela Martinez Cardona, Katherine Bell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 StudyBenoit You, Vasudha Sehgal, Balakrishna Hosmane, et al.
Pageof 5